Colorectal Cancer Clinical Trial
— NeoARTOfficial title:
Phase II Randomised, Double Blind, Placebo Controlled Trial of Neoadjuvant Artesunate in Stage II/III Colorectal Cancer
This study evaluates the safety and effectiveness of pre-operative artesunate given orally once a day for 14 days prior to surgery in patients with Stage II/III colorectal cancer. Artesunate is an established antimalarial drug with an excellent safety profile, is well tolerated and affordable. A number of laboratory studies and one small pilot clinical study in patients with colorectal cancer have shown that artesunate can reduce the proliferation and growth of cancer cells. Two hundred patients diagnosed with Stage II/III operable colorectal cancer will be randomly allocated to receive oral artesunate 200mg daily or a matching placebo for 14 days prior to surgery. Patients will be followed up closely for 5 years to see if giving artesunate preoperatively reduces the risk of cancer recurring after surgery.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | October 31, 2025 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria 1. Aged 18 or over 2. Histologically proven single primary site colorectal adenocarcinoma or high grade dysplasia plus unequivocal radiological evidence of invasive cancer 3. Stage II/III colorectal cancer planned for surgical resection and no clinical indication for neoadjuvant preoperative chemotherapy/chemoradiation therapy 4. WHO performance status 0,1 or 2 5. Adequate full blood count: White Cell Count (WCC) >3.0 x 10^9 /l; Platelets >100 x 10^9/l; Haemoglobin (Hb) >80g/L 6. Adequate renal function: Glomerular Filtration Rate >30ml/min by Cockcroft-Gault formula 7. Adequate hepatobiliary function : Bilirubin < 3 x Upper limit normal 8. Female participants of child bearing potential must have a negative pregnancy test < 72 hours prior to initiating study intervention and agree to avoid pregnancy using adequate, medically approved contraceptive precautions for up to 6 weeks after the last dose of study treatment intervention 9. Male participants with a partner of childbearing potential must agree to use adequate, medically approved contraceptive precautions during and for up to 6 weeks after the last dose of the study treatment intervention 10. Patient able and willing to provide written, informed consent for the study. Exclusion criteria 1. Contraindication to the use of artesunate due to hypersensitivity 2. Pregnancy or lactation 3. Male or female participants unwilling to use an effective method of birth control (either hormonal in the form of contraceptive pill or barrier method of birth control accompanied by the use of a proprietary spermicidal foam/gel or film); or agreement of true abstinence from time to consent is signed until 6 weeks after the last dose of study treatment intervention (i.e. withdrawal, calendar, ovulation, symptothermal and post ovulation methods are not considered acceptable methods) 4. History of immunosuppression 5. History of hearing or balance problems 6. Weight < 52kg or > 110kg 7. Other planned intervention, apart from standard of care 8. Any other malignant disease diagnosis within the preceding 2 years with the exception of non-melanomatous skin cancer and carcinoma in situ 9. Lactose intolerance |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Barking, Havering and Redbridge University Hospitals NHS Trust | Barking | |
United Kingdom | Ashford & St Peters Hospital NHS Foundation Trust | Chertsey | |
United Kingdom | University Hospitals of Derby and Burton NHS Foundation Trust | Derby | |
United Kingdom | Medway Maritime Hospital | Gillingham | Kent |
United Kingdom | St George's University Hospitals NHS Fundation Trust | London | |
United Kingdom | Kent Oncology Centre, Maidstone Hospital | Maidstone | Kent |
United Kingdom | Norfolk & Norwich University Hospitlas NHS FT | Norwich | |
United Kingdom | Shrewsbury and Telford Hospital NHS Trust | Shrewsbury |
Lead Sponsor | Collaborator |
---|---|
St George's, University of London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recurrence free survival at 2 years | 2 years following study randomisation. | ||
Secondary | Recurrence free survival at 5 years | 5 years from study randomisation | ||
Secondary | Overall survival at 2 and 5 years | 2 and 5 years from study randomisation | ||
Secondary | Colon cancer specific death at 2 and 5 years | 2 and 5 years from study randomisation | ||
Secondary | Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment at Day 7 following start of study intervention (artesunate/matching placebo) | ||
Secondary | Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment at Day 14 following start of study intervention (artesunate/matching placebo) | ||
Secondary | Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment at Day 42 following start of study intervention (artesunate/matching placebo) | ||
Secondary | Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment at Day 7 following study intervention | ||
Secondary | Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment at Day 14 following study intervention | ||
Secondary | Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment at Day 42 following study intervention | ||
Secondary | Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment 6 months following study intervention | ||
Secondary | Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment 12 months following study intervention | ||
Secondary | Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment 18 months following study intervention | ||
Secondary | Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment 24 months following study intervention | ||
Secondary | Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment 30 months following study intervention | ||
Secondary | Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment 36 months following study intervention | ||
Secondary | Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment 42 months following study intervention | ||
Secondary | Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment 48 months following study intervention | ||
Secondary | Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment 54 months following study intervention | ||
Secondary | Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 | Assessment 60 months following study intervention | ||
Secondary | Pathological assessment of tumour regression (involvement of lymph nodes; serosa; resection margin) | Post surgical pathology review (following Day 14 of study intervention) | ||
Secondary | Patient quality of life | Using validated quality of life self-administered questionnaires | Assessment at Day 1 of study intervention | |
Secondary | Patient quality of life | Using validated quality of life self-administered questionnaires | Assessment at Day 7 of study intervention | |
Secondary | Patient quality of life | Using validated quality of life self-administered questionnaires | Assessment at Day 14 of study intervention | |
Secondary | Patient quality of life | Using validated quality of life self-administered questionnaires | Assessment at Day 42 of study intervention | |
Secondary | Surgical complications | Number of patients with surgery related adverse events as assessed by CTCAE v4.0 | From time of surgery up to 3 months post surgery | |
Secondary | Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy | Assessment at Day 1 of study intervention | ||
Secondary | Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy | Assessment at Day 7 of study intervention | ||
Secondary | Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy | Assessment at Day 14 of study intervention | ||
Secondary | Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy | Assessment at Day 42 of study intervention | ||
Secondary | Immunohistochemical analyses of paraffin-embedded tumour sections to assess Kirsten rat sarcoma viral oncogene homolog (Kras) mutation status | Number of patients with Kras mutant tumours | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | |
Secondary | Immunohistochemical analyses of paraffin-embedded tumour sections to assess Mismatch Repair (MMR) status | Number of patients with Mismatch Repair (MMR) mutant tumours | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | |
Secondary | Immunohistochemical analyses of paraffin-embedded tumour for v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation status | Number of patients with BRAF mutant tumours | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | |
Secondary | Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor (PDGF) expression | Number of patients whose tumours show PDGF upregulation/downregulation following treatment intervention | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | |
Secondary | Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor receptor (PDGFR) expression | Number of patients whose tumours show PDGFR upregulation/downregulation following study intervention | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | |
Secondary | Immunohistochemical analyses of paraffin-embedded tumour for Vascular endothelial Growth Factor (VEGF) expression | Number of patients whose tumours show VEGF upregulation/downregulation following study intervention | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | |
Secondary | Immunohistochemical analyses of paraffin-embedded tumour on Vascular endothelial Growth Factor Receptor (VEGFR) expression | Number of patients whose tumours show VEGFR upregulation/downregulation following study intervention | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | |
Secondary | Determination of proliferative activity (Ki-67 staining, Cluster of Differentiation 31 protein (CD31) staining) | Number of patients whose tumours show an increase or reduction in proliferation markers Ki67 and CD31 following study intervention | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | |
Secondary | Determination of activation of the Deoxyribonucleic acid damage response (DDR) pathway | Number of patients whose tumour samples show activation of the DDR pathway following study intervention | Pre and post intervention tumour samples from patients (Day 0 and Day 15) | |
Secondary | Wnt/ß-catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins) | Number of patients who show an increase or a decrease in expression of proteins involved in the Wnt/ß-catenin proliferation pathway (e.g. c-myc and cyclinD1 proteins) following study intervention | Pre and post intervention tumour samples from patients (Day 0 and Day 15) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |